# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

> **NCT03002025** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64304500
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03002025
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2017-09-09
- **Final completion:** 2017-09-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002025, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03002025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*